Men with advanced prostate cancer in northern France now have access to a targeted nuclear medicine treatment closer to home.
The Boulogne-sur-Mer hospital center announced on November 20 it has begun offering lutetium-177–PSMA, a therapy that delivers radiation directly to cancer cells throughout the body, according to Actu. This development eliminates the need for patients to travel to major centers in Lille or Paris for this complex care.
How Radioactive ‘Smart Bomb’ Seeks Out Tumors
The treatment hinges on a clever biological mechanism. It couples a radioactive isotope, lutetium-177, to a molecule that targets prostate-specific membrane antigen (PSMA), a protein overexpressed on 75 to 95 percent of prostate cancer cells. Once infused intravenously, the compound travels through the bloodstream, attaches to metastases wherever they may be, and irradiates them from within while largely sparing healthy tissue.
The process is two-step. Patients first undergo a PSMA PET scan using a weakly radioactive tracer to confirm the target is present on their tumors. If the scan “lights up,” they receive the therapeutic infusion on an outpatient basis, the hospital confirmed.
A Certified Center, No Travel Required
The Boulogne-sur-Mer center earned the Haute Autorité de Santé’s “Qualité des soins confirmée” certification this year. This accreditation allows it to manage the complex logistics of the radiopharmaceutical, including cold-chain delivery, radiation-safety protocols, and multidisciplinary tumor-board review locally.
“A modern, efficient and humane management, delivered on an outpatient basis within our establishment,” the hospital said in its release.
Hope for Earlier Use, Screening Debate
Researchers are testing whether giving lutetium-177–PSMA alongside or instead of chemotherapy in men with fewer metastases could be more effective. Early-phase studies are evaluating actinium-225 and terbium-161 coupled to PSMA-targeting molecules. A Cochrane review in June concluded systematic screening reduces prostate-cancer deaths by about two per 1,000 men screened over 16 years.
A 2019 Swedish trial in European Urology, however, found a 21 percent mortality reduction. Since 2017, French guidelines have recommended active surveillance for low-risk tumors to avoid overdiagnosis and overtreatment, noted urologist Yann Neuzillet of Hôpital Foch.
Boulogne-sur-Mer, a sub-prefecture of Pas-de-Calais on the Côte d’Opale, was the main Roman port for trade with Britain under the name Gesoriacum. Its 12th-century belfry is recognised by UNESCO as a World Heritage Site. The city is also France’s largest fishing port, specialising in herring.
New Treatments Already in Development
The next generation of radioligands is already being tested. Early-phase studies are evaluating actinium-225 and terbium-161 coupled to PSMA-targeting molecules, according to Sciences et Avenir. Prostate cancer remains the most commonly diagnosed cancer in French men, with roughly 60,000 new cases annually. Metastases are present in 10 to 15 percent of diagnoses, and 20 to 40 percent of initially localized cancers eventually become metastatic, according to figures from the Institut national du cancer.
Worth a look